Despite combinatorial targeted therapies based on the latest understanding of signaling circuitry,5 patients with BRAF(V600E) mutant CRC only show modest clinical benefit from the BRAF plus EGFR inhibitor combination. This evidence concerns the gene EGFR and colorectal carcinoma.